Table 7.
Triple combinations for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting |
Sample size | Follow-up (median months) | Objective response rate (%) | Progression-free survival (median months) |
Overall survival (median months) |
| MEDIOLA (Drew et al. 2020)58 | II | Olaparib+ durvalumab + bevacizumab |
Recurrent platinum-sensitive non-germline BRCA-mutated ovarian cancer | 32 | Not reported | 77.4% | 14.7 | Not reported |
| OPAL (Liu et al. 2021)13 | II | Dostarlimab+ niraparib + bevacizumab |
Recurrent, platinum-resistant ovarian cancer | 41 | Not reported | 17.9 | 7.6 | Not reported |
| GINECO BOLD (Freyer et al. 2021)47 | II | Durvalumab+ bevacizumab +olaparib |
Recurrent platinum-sensitive/resistant advanced high-grade ovarian cancer |
74 | 15.5 | Not reported | 4.1 months in platinum-resistant disease; 4.9 months in platinum-sensitive disease | 18.8 months in platinum-resistant disease; 18.5 months in platinum-sensitive disease |
BRCA, BReast CAncer gene.